| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| LURASIDONE
| LURASIDONE | NERVOUS SYSTEM | ORAL | VD 6173 LITER (40 MILLIGRAM) PPB 99 PERCENT Cl 234 LITER / HOUR (40 MILLIGRAM) HT 18 HOUR (40 MILLIGRAM) SOLUBILITY VERY SLIGHTLY SOLUBLE IN WATER | DOPAMINE D2 ANTAGONIST (KI=0.994 NANOMOLAR) 5-HT2A ANTAGONIST (KI=0.47 NANOMOLAR) 5-HT7 ANTAGONIST (KI=0.495 NANOMOLAR) ALPHA2C-ADRENERGIC RECEPTOR ANTAGONIST (KI=10.8 NANOMOLAR) 5-HT1A RECEPTOR PARTIAL AGONIST (KI=6.38 NANOMOLAR) ALPHA2A ADRENERGIC RECEPTORS ANTAGONIST (KI=40.7 NM) | DOPAMINE D2 RECEPTOR ANTAGONIST CHEMBL217 DOPAMINE D2 RECEPTOR P14416 D(2) DOPAMINE RECEPTOR HOMO SAPIENS MEMBRANE RECEPTOR 7TM1 SMALLMOL MONOAMINE RECEPTOR DOPAMINE RECEPTOR | EMA | |||
